Oxford Biomedica signs LSA with Juno Therapeutics
Cell and gene focused CDMO Oxford Biomedica (OXB) has signed a licence and clinical supply agreement which could be worth up to USD227 million with Juno Therapeutics, the firms announced Wednesday.
The agreement allows Juno Therapeutics – a Bristol Myers Squibb subsidiary -- to use OXB’s LentiVector platform for its CAR-T and TCR-T programmes in oncology and other indications while establishing an initial five-year clinical supply agreement.
Under the terms of the LSA, OXB will receive USD10 million upfront in cash, a potential USD86 million dependent on it reaching certain development and regulatory milestones and a further $131 million in sales-based milestone payments and an undisclosed royalty on net sales of products developed using LentiVector.
OXB will also receive payments from process development and scale-up projects relating to the GMP manufacture of lentiviral vectors for use in clinical trials.
In return, Juno Therapeutics will also have access to OXB’s new 7,800 m2 commercial manufacturing centre OxBox, in Oxford, UK. OXB said it is already working on four undisclosed active projects, with Juno able to add projects in the future.
“This is the second company that has committed to working with us in our new OxBox facility, which we expect to be producing GMP vector by the end of the first half 2020,” said OXB chief executive John Dawson. “Today’s announcement further validates our decision taken in 2018 to invest in and scale up our GMP manufacturing facilities for clinical and commercial viral vector manufacture to support both existing and new partners and customers as well as the expected demand from industry.”
Related News
-
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
Sponsored Content CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance